Avnet May Deserve Some Love; Elevance Faces Policy Risk, and BNY Still Looks Stuck

Wall Street is bearish on all three, but only Avnet looks over-penalized

Wall Street is bearish across all three names, and that matters because bearish forecasts are uncommon in an industry where firms usually avoid public criticism. Even so, the reasons for pessimism are different. Avnet looks sentiment-driven, BNY looks merely fair, and Elevance still has a real policy overhang.

The target tree makes that mismatch fairly clear. Avnet carries a consensus price target of $89, implying a negative 4.1% implied return. That is more than standard caution. BNY also has an unappealing setup, but for the opposite reason: a consensus target of $142.85 leaves only a 0.1% implied return, which looks fair rather than compelling. Elevance sits in between. Management raised its 2026 adjusted EPS guidance to at least $26.75, showing some operating strength, but the stock still carries risk after unadjusted EPS guidance was cut to at least $19.85 from at least $22.30.

The near-term catalyst should clarify where expectations need to reset. Avnet is the only name where consensus still appears anchored to old pain rather than a live rerating path. If the rebound holds, fear can unwind quickly. If it does not, the bears will get fresh proof.

Avnet: the bear case is real, but it is still tied to the last cycle

The bear case still makes sense, but it is anchored to the wrong part of the cycle. Over the last two years, sales were flat and earnings per share fell by 17.7% annually. Investors do not forget that kind of damage easily, and a recovery that is only starting to show up can look less reliable than the last bad stretch.

That helps explain why the Street can stay negative even as the operating picture improves. The latest report gives investors a newer reference point: Electronic Components Sales growth of 34% year over year, while sequential operating income grew more than twice as fast as sales and sequential diluted EPS grew more than three times as fast. That is the key signal. When earnings expand faster than operating income, and operating income expands faster than sales, it suggests leverage is building rather than demand simply ticking up for a quarter.

Bears are not wrong to want proof. Cyclical rebounds can be deceptive, and one strong quarter can still be dismissed as noise. But the burden has shifted. Avnet does not need a perfect year to force a rerating. It needs another quarter that shows profit leverage is holding as growth broadens.

Elevance has operating progress, but policy risk still dominates

Elevance: better guidance does not erase the CMS overhang

Elevance recently gave investors something positive: a raise. The company raised its 2026 adjusted EPS guidance to at least $26.75 from at least $25.50, which suggests core operating pressure has eased enough for management to get more confident. But the stock still has to deal with a messy external shock.

The problem is not just the dollar amount. It is the lack of control. Elevance disclosed a potential liability range of $350 million to $1.5 billion tied to Medicare Advantage data compliance, while also cutting its unadjusted EPS guidance to at least $19.85 from at least $22.30. That gap between adjusted and unadjusted outlook matters because investors can usually absorb tougher conditions inside the business more easily than earnings hits driven by regulators or policy enforcement.

In Medicare Advantage, reimbursement quality, regulator optics, and enrollment stability are part of the economic model. Bulls can argue the issue is manageable if cure steps reduce the chance of broader sanctions. Skeptics will argue the opposite: when a large payer is dealing with a CMS cleanup and a multi-hundred-million-dollar exposure, investors are likely to stress-test the franchise more carefully.

Watchpoints: - any change in the CMS timeline - whether the liability range of $350 million to $1.5 billion narrows or expands - whether adjusted EPS guidance of at least $26.75 keeps diverging from unadjusted results

BNY is not broken, but the setup still looks mediocre

BNY's problem is the opposite of Avnet's. There is no drama, but there is also no clear reason for the multiple to expand. The business looks steady rather than exceptional, and that kind of profile can disappoint when investors decide they want faster or more profitable compounding.

Avnet had a sentiment reset with operating proof behind it. Elevance still has a live policy overhang that can surprise outside earnings. BNY has no dramatic overhang, but it also does not present a mismatch large enough to force a repricing. One faces optics risk. The other faces valuation indifference.

Positioning: one rebuild setup, one wait-for-clarity name, one avoid

Across these names, the clearest trade is to act where expectations and operating reality are diverging, and to stay selective where they are not.

Avnet: start a rebuild position

• Posture: Start a rebuild position. The market is still underwriting the old cycle even though Avnet has already delivered first-quarter sales of $5.9 billion and more recent strength including Electronic Components Sales growth of 34%, with earnings expanding faster than revenue.
• Trigger: Add only if the next print shows that profit leverage is holding, not just a one-quarter demand bounce.
• Why now: Bearish consensus is uncommon in a market where analysts usually hesitate to turn negative, so the setup can rerate quickly once the Street stops seeing stale cycle pain.
• Invalidation: If growth stops without a fresh margin push, treat it as a failed recovery and scale back.

Elevance: wait for clarity

• Posture: Wait-and-see, not avoid. The business is strong enough to keep lifting outlook, with raised 2026 adjusted EPS guidance, but the headline risk is still prominent.
• Trigger: Revisit only if the policy overhang narrows and the gap between adjusted and unadjusted earnings stabilizes.
• Why now: The next update could either shrink the issue or remind investors that the exposure is still large enough to interrupt the story.
• Invalidation: If the liability range broadens or enforcement worsens, step aside.

BNY: avoid for now

• Posture: Avoid. Nothing dramatic is breaking, and that is the problem. A business with slow, asset-heavy compounding and only a 0.1% implied return from consensus targets does not stand out when better setups exist.
• Trigger: Come back only if BNY starts delivering more than steady results.
• Invalidation: If it remains merely decent at this price, patience is still the right call.